19/09/2014 01:48:35 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
09/18/20147:03PMBWMSD présente les premiers résultats d'une étude de phase III sur l'omarigliptine, un inhibiteur expérimental de la DPP-4 ...
L'omarigliptine a entraîné une diminution significative du taux d'hémoglobine A1c (HbA1c) par rapport au placebo La société MSD, connue sous le nom de Merck & Co., Inc. (NYSE : MRK) aux États-Unis et au Canada a présenté aujourd'hui les premiers résultats d'un programme de développement clinique de phase... More...>>
09/18/20141:40AMBWLa MSD presenta i primi dati di fase 3 su Omarigliption, un inibitore del DPP-4 per il diabete di tipo 2, somministrato una v...
L'omarigliptina ha ridotto in modo significativo i livelli di HbA1c rispetto al placebo La MSD, conosciuta negli Stati Uniti e in Canada come Merck & Co., Inc. (NYSE:MRK), ha annunciato oggi la presentazione dei primi dati del programma di sviluppo clinico di fase 3 della omarigliptina, l'inibitore di DPP-4 della MSD... More...>>
09/17/201410:25PMBWMSD präsentiert erste Daten der Phase-3-Studie an japanischen Patienten für Omarigliptin, einen einmal wöchentlich einzune...
Omarigliptin reduzierte die HbA1c-Werte im Vergleich zu Placebo signifikant MSD, in den USA und Kanada als Merck & Co., Inc. (NYSE:MRK) bekannt, kündigte heute die Präsentation der ersten Daten des klinischen Phase-3-Entwicklungsprogramm für Omarigliptin an, das Prüfmedikament von MSD, das einmal wöchentlich verabreicht... More...>>
09/17/20149:31AMBWMerck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for T...
Omarigliptin significantly reduced HbA1c levels compared to placebo Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor for the treatment... More...>>
09/17/20148:30AMBWSun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab
Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) through their respective subsidiaries, today announced an exclusive worldwide licensing agreement for Merck’s investigational... More...>>
09/15/20141:30PMBWMerck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatm...
Merck now expects to submit the New Drug Application for odanacatib with the U.S. Food and Drug Administration (FDA) in 2015 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis... More...>>
09/08/20145:00PMBWMerck to Participate at the Morgan Stanley Global Healthcare Conference
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer; Adam H. Schechter, executive vice president and president, Global Human Health; and Dr. Roy Baynes, senior vice president, Clinical Development, Merck Research Laboratories... More...>>
09/05/20149:49AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Friday's session are Family Dollar Stores Inc. (FDO), Dollar General Corp. (DG) and Dollar Tree Inc. (DLTR). Family Dollar said its board unanimously rejected Dollar General's revised takeover bid, again citing antitrust concerns and reiterating its support... More...>>
09/04/20143:46PMPRNUSMerck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy PR Newswire WHITEHOUSE STATION, N.J., Sept. 4, 2014 WHITEHOUSE STATION, N.J., Sept. 4, 2014 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food... More...>>
09/04/20143:30PMDJNFDA Approves Merck's Cancer Drug
U.S. regulators on Thursday approved a new kind of cancer drug from Merck & Co. that is designed to unleash the body's immune system against tumors and could generate billions of dollars in sales. The drug, which Merck plans to sell under the brand name Keytruda, is part of a long-anticipated wave of medicines that... More...>>
09/04/20143:15PMBWMerck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab... More...>>
09/04/20149:00AMBWMerck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) &...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the company’s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track... More...>>
09/02/20148:30AMBWMerck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company’s Investigational Anti-PD-...
First Presentation of Findings in Gastric and Bladder (Urothelial Tract) Cancers Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody... More...>>
08/26/201410:05AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Tuesday's session are Best Buy Co. (BBY), Burger King Worldwide Inc. (BKW) and DSW Inc. (DSW). Best Buy posted a stronger-than-expected quarterly profit as the electronics retailer's cost-trimming and e-commerce initiatives started to pay off, though sales continued... More...>>
08/26/20148:00AMBWPfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen
Agreement to Combine Merck’s Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer’s Crizotinib (XALKORI®) in Clinical Trial Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE:MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement... More...>>
08/15/201411:00AMDJNGilead Notches Victory in Hepatitis C Drug Race
Gilead Sciences Inc. on Friday said it scored a key victory in securing the rights to its hepatitis C treatment, after an arbitration panel ruled in its favor over Roche Holding AG's claim on the lucrative drug. The panel ruled on Thursday that Roche failed to establish any of its claims to sofosbuvir, the key ingredient... More...>>
08/15/20149:00AMPRNUSCelebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics Wit...
Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal Culinary Expert Visits San Antonio on August 16 to Help Educate At-Risk Population About Ingredients for Successful Blood Sugar Management PR Newswire WHITEHOUSE... More...>>
08/14/20149:00AMPRNUSAward-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals Merkerson Visits Dallas, Texas on August 14 With America's Diabetes Challenge: Get to Your Goals Program PR Newswire WHITEHOUSE STATION, N.J., Aug. 14, 2014 WHITEHOUSE STATION, N.J., Aug. 14, 2014... More...>>
08/13/20145:58PMBWMerck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumo...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices’ (ACIP’s) updated pneumococcal vaccine recommendations for adults 65 years of age and... More...>>
08/13/20144:49PMBWFDA Approves BELSOMRA® (suvorexant) for the Treatment of Insomnia
BELSOMRA expected to be available in late 2014 or early 2015 Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk140919 01:48